Business Wire

WA-KARAT

13.10.2021 14:02:12 CEST | Business Wire | Press release

Share
Karat Pioneers the Interviewing Cloud to Transform Technical Hiring, Secures $110M in Series C Funding

Karat , the world leader in technical interviewing and pioneer of the Interviewing Cloud , today announced a $110 million Series C funding round at a $1.1 billion valuation. Karat’s industry-defining human + technology solution delivers live technical interviews on behalf of clients 24/7 while forging deep strategic partnerships that unlock enormous value for engineering and talent acquisition leaders.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211013005399/en/

Software engineers are the lifeblood of the modern organization, and the gap between the supply of talent and demand will continue to widen in the coming decades. In the race to hire, companies are investing $60 billion a year of engineering time spent interviewing. Yet, despite that investment, most organizations don’t have enough bandwidth to interview at the necessary scale and velocity to compete for top talent. Furthermore, the time that is being invested is ineffective as do-it-yourself interviews fail to create a structured, consistent, and candidate-centric hiring process.

“Just like the public cloud moved everyone from private computing to shared infrastructure, Karat’s Interviewing Cloud is upending the old way of do-it-yourself interviewing that eats into valuable engineering time and fails to delight candidates,” said Mohit Bhende, Karat co-founder and CEO. “By professionalizing interviewing and developing purpose-built interviewing technology, Karat enables companies to innovate faster and candidates to showcase their strengths in a comfortable environment.”

The twofold benefit of reclaiming engineering time and accelerating technical hiring is driving massive adoption of the Interviewing Cloud. Karat has tripled bookings and doubled its number of customers over the past year. In addition to the rapid growth, Karat continues to deepen its partnerships, with the average enterprise client doubling their contract size year-over-year, including eight companies now spending more than $1M per year.

“Karat’s Interviewing Cloud has been a game-changer for us. We’ve gotten back over 25,000 hours of developer time that we’re able to spend innovating and building products," said Joseph Sirosh, CTO at Compass. "Our candidates love the Karat experience and they move more quickly through the process. Without Karat, it would have been a challenge to grow our engineering team at the pace that we have, and with the high talent bar that we have.”

Karat’s impressive growth and market opportunity motivated inside-investors, including Norwest Venture Partners, 8VC, Exor, Base Partners, and Sempervirens Fund, to join Tiger Global in expanding their investments. Collectively, these investors account for 99% of the latest capital raise.

"We believe Karat’s human + technology Interviewing Cloud is the way most companies will hire engineers,” said Scott Shleifer, partner at Tiger Global. “We know the gap between the supply of engineering talent and demand will continue to widen and are excited to deepen our investment in the category creator and leader."

The new capital will allow Karat to rapidly scale its global infrastructure and go-to-market function to accelerate growth. Karat is also investing heavily in data science and interview innovation to unlock insights for companies and accelerate hiring processes for candidates. Karat’s market intelligence will deliver unparalleled benchmarking insights driven by the world’s largest cross-company interview dataset.

“Karat’s Interviewing Cloud has become a significant differentiator for how we hire engineers,” said Jonathan Kehoe, Director of Talent at Wayfair. “Karat is incredibly consistent and has data nobody else has, it’s like holding a mirror up to your full hiring process and seeing what’s working well and where you need to improve.”

The expertise and data generated from hundreds of thousands of interviews also allows Karat to create more candidate-centric experiences, particularly for software engineers who have been previously overlooked by traditional hiring practices.

“Innovations like the redo, candidate feedback and our Brilliant Black Minds program are giving candidates from nontraditional backgrounds more opportunities to break into tech and are creating more equitable hiring processes,” said Jeffrey Spector, Karat co-founder and President. “As we launch Karat’s next chapter of growth, delivering fair and inclusive candidate experiences continues to be our North Star.”

To learn more about Karat, visit karat.com .

About Karat

Karat created the world’s first Interviewing Cloud to solve the multi-decade global shortage of software engineers. The Interviewing Cloud is an always-on, scalable, and consistent human + technology solution for conducting predictive, fair, and enjoyable technical interviews 24/7. Karat’s global network of Interview Engineers, unparalleled market intelligence, and purpose-built interviewing infrastructure opens the pipeline for engineering talent, limits pedigree bias, and provides access for underrepresented candidates. The fastest growing and largest enterprises such as Roblox, American Express, Intuit, Compass, and Wayfair trust Karat to expand hiring capacity, unlock developer time, and raise engineering quality so they can innovate and grow. For more information, please visit: www.karat.com .

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye